TerminatedNCT01894984

An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

Observational studyAges 18–65

The study in practice

Understand this study

This study evaluates the safety and effectiveness of Risperidone for people with schizophrenia.

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateJanuary 2007

Recruitment status: Terminated
Enrollment listed in the registry: 640
Sponsor: Xian-Janssen Pharmaceutical Ltd.
Sponsor type: Pharmaceutical company
Study type: Observational
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Not clearly listed
Age range: From 18 Years to 65 Years
Official registry ID: NCT01894984
Official title: Show the full official title
Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China

Terminated

Locations not listed

FAQ

What is this study about?

This study evaluates the safety and effectiveness of Risperidone for people with schizophrenia.

Who is behind this study?

The study sponsor is Xian-Janssen Pharmaceutical Ltd., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including Risperidone and Oral atypical anti-psychotic.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.